Order Cheap Anastrozole in Online Pharmacy.
international and chemical name: anastrozole; 2, 2 ‘-[5-(1 h-1, 2, 4-triazole-1-ilmetil) -1, 3-1,4] bis (2-metilpropiononitril);
the main physico-chemical properties. round, oboevypuklye, white pills film-coated, with the “a” logo on the same Bokeh and labeled “Adx 1” is on the other;
Composition. 1 Tablet contains 1 mg anastrozola;
other ingredients: lactose monohydrate, sodium krahmalglikolât, polyvidone, magnesium stearate, metilgidroksipropilzelluloza, MACROGOL 300, titanium dioxide.
output form of the medication. Film-coated tablets.
pharmacotherapeutic group. Hormone antagonists and similar means. Enzyme inhibitors. ATC Code G03 L02B.
the action of medicines. ARIMIDEX is a potent and highly selective inhibitor of aromatase. In postmenopausal women estradiol is produced mainly by turning in the peripheral tissues of androstenedione in estrone using enzyme-aromatase. Estrone is further transformed into estradiol. Reduced levels of circulating estradiol exerts therapeutic effects in women with breast cancer. In postmenopausal women in a daily dose of Arimidex 1 mg produces a reduction in the level of estradiol at 80%. ARIMIDEX does not have progestogenic, androgenic activity. Arimidex in daily doses up to 10 mg has no effect on the secretion of cortisol and aldosterone, measured before and after ACTH stimulation test standard. Therefore replacement corticosteroids do not necessary. Patients with a negative test result for sensitivity to oestrogens efficacy has not been demonstrated, unless there was a previous positive clinical response to tamoxifen.
Suction anastrozola fast, the maximum concentration in plasma achieved within 2:00 (prandial). Anastrozole return slowly. The plasma half-life of 40-50 h. Food slightly decreases the speed of the binding, but not the degree of his induction. Small speed change induction should not result in clinically significant effects on a constant concentration of the drug in plasma when daily reception of 1 pill Arimideksa.
Approximately 90-95% of constant concentration is reached after 7 days of taking the drug. No information about the dependency of anastrozola farmakokineticeskih parameters of time or dose.
Pharmacokinetics anastrozola is not dependent on age in postmenopausal women. Anastrozola Pharmacokinetics was not studied in children.
Anastrozole binds to plasma proteins at 40%.Anastrozole extensively metabolized in postmenopausal women, less than 10% dose presented with urine unchanged to within 72 h. After the introduction of the dosage. The metabolism of anastrozola by n-dealkirovaniâ, hydroxylation and glucuronidation. Metabolites are excreted mainly with urine. Triazole-major metabolite, which appear in the plasma and urine is not inhibited by aromatase.
anastrozola is the ground, determined after oral admission for volunteers with stable cirrhosis of the liver or kidney dysfunction, do not differ from the ground clearance, which is determined in healthy volunteers.
indications for use. Common breast cancer among postmenopausal women.
As a medication for the treatment of early stage breast cancer in postmenopausal women with a positive test result for sensitivity to oestrogens, which it is impossible to use tamoxifen through high risk of thromboembolism or endometrial abnormalities.
The use and dosage.
The adults, including the elderly: by 1 mg within 1 times per day.Kidney: adjusting the dose in patients with mild and moderate kidney dysfunction is not necessary. The liver: adjusting the dose in patients with minor violations of the liver is not necessary.
ARIMIDEX is generally well tolerated. Adverse events were mainly light to moderate. Only in a few cases, treatment was suspended through the occurrence of undesirable effects. The drugs may cause some Arimideksa expect effects, including hot flashes, vaginal dryness and thinning hair. Sometimes patients who take Arimidex, there are violations of the gastrointestinal tract (anorexia, nausea, vomiting and diarrhea), fatigue, pain in the joints or reduction of their mobility, drowsiness, headache, or precipitation, including in some cases a violation on the part of the skin and mucous membranes, such as polymorphic erythema and Stevens-Johnson Syndrome. The causal link between the techniques of anastrozola and tromboèmboličeskimi complications is not installed. In clinical trials, there was no statistical difference between the installed častotoû thromboembolic complications with anastrozola 1 mg and megèstrola acetate, but with anastrozola 10 mg this frequency was slightly smaller.In patients with advanced breast cancer, most with which metastasized to the liver were observed, experienced the change of liver (elevation of g-gt and, rarely, alkaline phosphatase). The causal relationship of these changes is not government machinery regarding. During clinical trials Arimideksa also noted a slight increase in the level of total cholesterol.
ARIMIDEX is contraindicated in patients:
- in premenopausal women;
- during pregnancy and lactation;
- with severe kidney disorders (creatinine clearance below 20 ml\/min.);
- with liver failure;
- with known hypersensitivity to anastrozola or other substances contained in the
- product that marked on the package.
Cases of overdose not described. Arimidex in high doses are well tolerated. Treatment: specific antidote not. If necessary, symptomatic therapy, applied general supportive therapy and monitoring functions of the vital organs and systems. Dialysis is effective. Usage patterns. ARIMIDEX is not recommended in children.
in doubt in hormonal status of patients after menopause should be confirmed by the results of biochemical research.
no data about the safe use of Arimideksa in patients with moderate and severe violations of the liver and in patients with severely impaired renal function (creatinine clearance below 20 ml\/min).
Effects on ability to drive and operate moving mechanisms. It is unlikely that Arimidex affect this ability, but through messages about asteniû and drowsiness associated with Arimideksa techniques, it is recommended that you carefully approached until the question driving the car and work with mechanisms if you encounter these symptoms.
the interaction with other drugs. Clinical studies concerning drug interactions with antipirinom and zimetidine indicate that simultaneous use of Arimideksa with other drugs is unlikely to lead to clinically significant drug interactions resulting from the cytochrome p 450.
The study database relating to the safety of the drug, accumulated during the clinical trials did not reveal izvestnostej about clinically significant drug interactions in patients who were simultaneously Arimidex and other drugs that are often prescribed.
There is currently no izvestnostej about the use of Arimideksa in combination with other drugs protivoopujolevami.
Estrogens should not be appointed simultaneously with Arimideksom, because these drugs have an opposite pharmacological action.Storage conditions. Keep out of reach of children at a temperature below 30° c. Shelf life is 5 years.